Gilead Sciences, Inc. insider Andrew D. Dickinson reported a sale of company common stock on July 15, 2026. The Form 4 describes a transaction involving 3,000 shares of Gilead common stock sold at a weighted-average price of $129.9256 per share, implying aggregate proceeds of approximately $389,777 before commissions, taxes, or other costs. The sale was executed under a Rule 10b5-1 trading plan that Dickinson adopted on August 29, 2024. Such plans allow insiders to establish prearranged trading instructions at a time when they are not in possession of material nonpublic information, with later trades occurring according to the plan’s terms. The filing notes that the shares were sold at prices ranging from $129.45 to $130.08. Because the reported price is an average, the filer stated that full details on the number of shares sold at each separate price would be provided to the SEC, Gilead, or shareholders upon request. The document identifies the security as Gilead common stock. No option exercise, equity vesting event, or derivative-securities transaction is described in the provided text. The excerpt also does not state Dickinson’s beneficial ownership total after the sale. The filing was signed on Dickinson’s behalf by Amy Kim under power of attorney on July 16, 2026.